Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts

Regeneron executives highlighted continued growth in key marketed products, a broad late-stage development pipeline, and a science-driven approach to business development in discussions with Bernstein analyst Jeffrey Walch. The update supports a constructive outlook for the biotech's commercial portfolio and pipeline, but disclosed no new financial targets, clinical data, or transaction details.